The Wisconsin Department of Health Services has entered into a contract with publicly-traded company Pear Therapeutics to offer its reSET and reSET-O prescription digital therapeutics to Wisconsin residents with substance use disorder and opioid use disorder.
Pear's reSET, a mobile application used to help treat substance use disorder, received FDA De Novo clearance in 2017. The Boston-based...
Pear Therapeutics is launching a program to offer its prescription digital therapeutics for substance use disorder and opioid use disorder, reSET and reSET-O, via telehealth providers.
The first telehealth offering working with the prescription digital therapeutic company is PursueCare, which focuses on addiction medicine.
"We find patients are often required to piece together their treatment...
A "refill" of Pear Therapeutics’ reSET-O digital prescription therapeutic for treating opioid use disorder is associated with high levels of abstinence and treatment retention as well as fewer hospital encounters, according to a study published in Hospital Practice.
Most of the study’s authors are current or former Pear employees.
TOP-LINE DATA
Out of a group of 3,817 people who completed a 12-...
Pear Therapeutics’ reSET-O prescription digital therapeutic for opioid use disorder lowered healthcare costs and added quality life years post-treatment, according to a Pear-funded analysis published in the Journal of Market Access & Health Policy.
TOP-LINE DATA
Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years...
Pear Therapeutics' reSET-O, a prescription app for treating opioid use disorder, may lower patients’ health care costs, compared with patients who don’t use the app, according to a study published in the journal Hospital Practice.
“Engagement and continued treatment with reSET-O in patients with OUD treated with buprenorphine is associated with substantial real-world reductions in medical costs...
Prescription digital therapeutics startup Pear Therapeutics announced an $80 million Series D round this morning headed by SoftBank Vision Fund 2.
The raise included funds from new backers Forth Management, Pilot House, Sarissa Capital, Shanda Group and QUAD Investment Management, as well as from returning investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis,...
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer clinical encounters and subsequently decreased medical costs over a six-month period.
The study was funded by Pear, coauthored by a Pear employee and published in the journal Expert Review of...
Digital therapeutics company Pear Therapeutics has inked a deal with pharmacy benefits manager (PBM) RemedyOne, allowing the latter to offer and administer benefit coverage for the formers’ prescription-addiction-focused therapies reSET and reSET-O to its customers.
Both reSET and reSET-O have FDA clearances. In fact, reSET was the first software-only therapeutic to get the designation. reSET ...
Digital chronic care management company Livongo and health kiosk startup Higi have teamed up for a new program that will bring a Livongo-branded on-stage program to nearly 500 retail pharmacies in Michigan, the companies announced today. Through these and other channels, consumers will be able to measure indicators of chronic disease, enroll in Livongo programs, participate in health surveys and...
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics.
The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics.
“Pear and Sandoz previously signed...
